|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups.
|
26493382 |
2016 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma.
|
26061751 |
2015 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we compared the two groups of survival outliers of glioblastoma with IDH wild-type, consisting of the glioblastoma patients who lived longer than 3 years (n = 17) and the patients who lived less than 1 year (n = 12) in terms of genome-wide DNA methylation profile.
|
31159876 |
2019 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred twenty-six tumors could be classified: 20 as type II (IDH mutation [mut], "astrocytoma"), 49 as type I (1p/19q codeletion, "oligodendroglioma"), 55 as type III (7+/10q- or TERTmut and 1p/19q intact, "glioblastoma"), and 2 as childhood glioblastoma (H3F3Amut), leaving 7 unclassified (total 91% classified).
|
26354927 |
2016 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
|
27626492 |
2016 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The metabolic genes isocitrate dehydrogenase 1 (IDH1) and IDH2 are commonly mutated in low-grade glioma and in a subset of glioblastoma.
|
28980701 |
2017 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
|
29617848 |
2019 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
|
26503470 |
2015 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>.
|
29921698 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis.
|
29741737 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples.
|
20171178 |
2010 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
|
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IDH activity was the main provider of NADPH in human normal brain and glioblastoma, but its role was modest in NADPH production in rodent brain and other tissues.
|
21527585 |
2011 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presented approach is applicable for prospective validation and appears promising towards an effective glioblastoma patient stratification in addition to IDH mutations.
|
23250732 |
2013 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified a subset of tumors (n = 18, 8.8% of high-grade gliomas) exhibiting moderate-to-strong immunoreactivity that enriched for the IDH-wild-type glioblastoma variants gliosarcoma (n = 10) and the newly described epithelioid glioblastoma (n = 4).
|
28789475 |
2017 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in IDH genes are observed in over 70% of low-grade gliomas and some cases of glioblastoma.
|
26485760 |
2015 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
|
26158269 |
2015 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment.
|
29920451 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients were diagnosed with IDH-wild type glioblastoma according to pathological criteria.
|
29212499 |
2017 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma multiforme (pGBMs) were analyzed for BRAF V600E, IDH1, IDH2, and TP53 mutations.
|
24057326 |
2013 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the new histomolecular classification, diagnoses included anaplastic oligodendroglioma IDH mutant and 1p/19q-codeleted (32.5 %), anaplastic astrocytoma IDH mutant (IDH (mut)) (11.0 %), anaplastic astrocytoma IDH wild type (IDH (wt)) (5.3 %), glioblastoma IDH (mut) (17.1 %), and glioblastoma IDH (wt) (33.2 %).
|
27573687 |
2016 |
|
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
|
25150284 |
2014 |